The last of the loose ends have seemingly been tied down, as Alvotech announced on March 8 that it has come to a licensing agreement with AbbVie. The agreement halts remaining patent litigation between the parties, and assumably, pays AbbVie a royalty on sales of AVT02.
Alvotech’s adalimumab biosimilar candidate is a high-concentration, citrate-free formulation. The Iceland-based company’s application as an interchangeable biosimilar was accepted by the FDA last month. If approved, this would be the second interchangeable adalimumab to launch in July 2023 (Boehringer Ingelheim’s Cyltezo® was first).